OC-0266
Air-liquid culture system from primary cells to study normal tissue effects of combination therapies for lung cancer R. Iannone 1 , E. Moreno Roig 1 , R. Habets 1 , L. Barbaeu 1 , N. Reynaerts 1 , M. Vooijs 1 1 Maastricht Radiation Oncology (MAASTRO) GROW -School for Oncology and Development, Radiotherapy, Maastricht, The Netherlands Purpose/Objective: Treatment of lung cancer with combinations of surgery, chemotherapy, and radiotherapy (RT) is a major challenge because of dose limiting toxicities of the surrounding normal tissue, preventing tumor control. A better understanding of normal tissue damage response and repair after treatment is needed to improve local control, QoL and outcome. The NOTCH pathway is a key regulator of normal lung development and it is important in lung cancer progression and response to RT. Notch inhibitors are currently being tested in clinical trials but little is known on how normal lung tissue is affected. Materials and Methods: In order to study the effect of novel radio-sensitizers in different combination treatments on normal lung tissue we used a multilayer 'air-liquid interface' culture system from primary bronchial epithelial patient derived cells (PBEC). These cultures are typically composed of proliferative basal cells and the differentiated ciliated and mucous producing cells. The expression of Notch receptors, ligands and target genes was determined using qPCR and Immunoblotting. Results: Here, we studied cell population changes in the multilayer bronchial epithelium under normal conditions and after treatment with Notch inhibitors and/or radiation. Upon treatment with NOTCH inhibitors ciliated cells increased at the expense of the mucous lineage whereas Notch activation increased mucous cell populations. These changes were consistent with cell-type specific marker expression and NOTCH specific target gene expression. The data presented will be on the consequences of different scheduled treatments including Notch inhibitors and (fractionated) irradiation. Conclusions: The multilayer 'air-liquid-interface' culture system provides an ideal model for studying cell fate changes upon therapy in normal broncho-epithelial cells. The Notch pathway plays a key role on the regulation of the cell fate decision in our model.
OC-0267
The impact of an adult radiation late effects clinic on breast cancer survivorship W. Levin 1 , R. Dinniwell 1 1 Princess Margaret Cancer Centre University of Toronto, Radiation Oncology, Toronto, Canada Purpose/Objective: Radiotherapy is a key modality within the multidisciplinary management of breast cancer. A late effect (LE) following radiotherapy for breast cancer may occur many months or years afterwards, present significant management issues and adversely impact quality of life. To identify the LE prevalence, management and potential needs in breast survivorship an audit was performed of the patients referred to the Adult Radiation Late Effects Clinic at a tertiary care centre. 3rd ESTRO Forum 2015 S137 T2; and N stage was: 25 Nx, 65 N0, 26 N1, 1 N3. Mastectomy was performed in 17 and wide local excision in 100. Axillary dissection was done in 67 and sentinel node dissection in 33 with a median number of 13 (1-24) lymph nodes excised. 52 received chemotherapy and 72 endocrine therapy. All received radiotherapy (1 neo-and 116 adjuvant) with 67 breast/chest wall alone and 40 breast/chest wall and regional nodal irradiation. The median time to onset of LE from the completion of radiotherapy was 0.5 y (0.1 to 7.8). LEs included: 38 truncal and/or breast pain; 24 arm lymphedema; 16 breast inflammation; 16 breast lymphedema; 14 neck, truncal, breast fibrosis; 9 tissue ulcer/necrosis; 2 brachial plexopathy 2; and 11 other. Following LE consultation, 90 received pharmacologic (18 anti-inflammatory, 60 anti-oxidant, 12 pentoxifylline or 4 other) and/or non-pharmacologic management (33 selflymphatic massage). Transient mild toxicities were observed in 8 (9%) (4 GI, 2 MSK, 2 pre-syncope). No major toxicities from LE treatment occurred. Moderate to significant improvement was observed in 78 (87%) with12 patients demonstrating no improvement. Conclusions: Following completion of therapy, acute toxicities may persistent or late toxicities arise. For women with these toxicities, current interventions appear to have a meaningful impact upon LE's with minimal side effects. Recognition of the potential to manage persistent acute effects and LE's is important and needs to be better incorporated within breast cancer survivorship to best improve aftercare.
Materials and Methods

OC-0268 A Dutch nationwide survivorship care programme for (non-
Purpose/Objective: Survivors of Hodgkin lymphoma (HL) and subgroups of non-Hodgkin lymphoma (NHL) are at increased risk of various late adverse effects of radiotherapy and chemotherapy, leading to substantial excess morbidity and mortality. The need for long-term follow-up is increasingly recognized. Long-term follow-up care programmes have been established for childhood cancer survivors, but not yet for (N)HL survivors. Therefore, the Dutch BETER consortium (Better care after Hodgkin lymphoma: Evaluation of longterm Treatment Effects and screening Recommendations) has developed a nationwide infrastructure for survivorship care clinics for survivors of HL and subgroups of non-Hodgkin lymphoma (diffuse large B-cell lymphoma). The consortium aims to: 1) establish evidence-based follow-up guidelines for (N)HL survivors; 2) identify and trace survivors eligible for follow-up care; 3) educate survivors about possible late adverse effects of treatment; and 4) provide risk-based care and advice regarding prevention. Materials and Methods: Follow-up guidelines were developed according to international standards. The guideline development group consisted of clinicians, methodological experts and patient representatives. We developed guidelines for second malignancies, cardiovascular disease, thyroid disease and osteoporosis after premature menopause. Recommendations are given for fertility care and family planning, therapy for neck muscle weakness, and infection prophylaxis for functional asplenia. Results: We are currently identifying and tracing a cohort of approximately 8,500 HL survivors and 3,000 NHL survivors in 22 hospitals throughout the Netherlands, including all radiotherapy centres. Eligible patients for follow-up care survived for ≥5 years and were treated at ages 15-70 years from 1970 onwards. Survivors are identified through the Netherlands Cancer Registry, the nationwide pathology registry and hospital-based registries. Tracing of current addresses of survivors is done through the nationwide Netherlands Personal Records Database. For all survivors, treatment data are collected from medical records to provide risk-based screening recommendations. The website www.beternahodgkin.nl was developed to inform and educate survivors about late effects. Currently, a survivorship care plan is being developed. A nationwide database, including screening and adverse events data, is being developed to evaluate the follow-up guidelines for diagnostic value and efficacy. Conclusions: We expect that the BETTER project will improve healthy life expectancy and quality of life for (N)HL survivors. Evaluation of follow-up care will lead to improved knowledge regarding the diagnostic value and efficacy of the
